Neopeutics General Newsletter: Here and Beyond

We welcome you to a brief newsletter put out by our San Francisco office monthly. We hope to use this opportunity to update our partners and collaborators on progress at Neopeutics and within our projects (the"Here") and in the healthcare and wellness world at large (the "Beyond"). We hope you will enjoy this brief summary, and look forward to your comments and additions through the email given below. This our first edition, May 2016.

Business: May Newsletter

With the 2nd Quarter of 2016 coming to an end soon, biotech companies are working to improve their sales to meet annual targets. In the market, Allergan is expected to purchase back $10 billion of their stock after an excellent first quarter that saw a 48 percent increase in sales. Why such a big boost? Botox, Restatis, and their new drug, LINZESS® (linaclotide, for the treatment of irritable bowel syndrome with constipation. As of May 11, 2016, Allergan’s stocks sit at $230.37.

The stock repurchasing is in response to their acquisition by Israeli-based Teva, with Allergan intending to purchase back $4-5 billion in open market repurchases if market conditions prove suitable. Teva’s purchase of Allergan will provide a much-needed cash injection into Dublin-based Allergan, allowing the innovative but cash-strapped company to reduce some of the debt it carries and to stimulate additional growth.

Allergan is also undergoing some internal management shuffles. Bill Meury, who oversaw the company’s branded drug sales will become Allergen’s chief commercial officer, while Bob Stewart has been appointed as the new chief operating officer.